Clinuvel Pharmaceuticals CEO Philippe Wolgen must be a serious flight risk.
How else to explain the spoils that year upon year accrue for the “unusual”, “amazing” and “extraordinary” executive (his chairman’s words). For the second year running, Wolgen’s cash take alone has equated to more than 5 per cent of the company’s annual revenues.
Loading...
Myriam Robin is Rear Window editor based in the Melbourne newsroom. A Rear Window columnist since 2017, she previously reported on financial markets and media. Connect with Myriam on Twitter. Email Myriam at myriam.robin@afr.com
